Baseline PSA values from age 65 to 69 years may be highly informative for adverse prostate cancer outcomes after age 70 years, with a PSA of less than 1 ng/mL associated with a very low risk of long-term PCSM and mPCa. This evidence concerns the gene KLK3 and prostate carcinoma.